CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05335993
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:04.265465+00:00
Published At: 2026-04-03T00:00:00+00:00
Record Updated At: 2026-04-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Ovarian Cancer", "Recurrent Epithelial Cancer of Ovary", "Recurrent Epithelial Ovarian Cancer", "Recurrent Fallopian Tube Cancer", "Peritoneal Cancer", "Recurrent Carcinoma of Ovary", "Adenocarcinoma of Ovary"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-03"
protocolSection.identificationModule.nctId: "NCT05335993"
protocolSection.identificationModule.officialTitle: "Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.